[en] BACKGROUND & AIMS: It is a challenge to manage patients with ulcerative proctitis (UP) refractory to standard therapy. We investigated the effectiveness of tumor necrosis factor (TNF) antagonists in a large cohort of patients with refractory UP. METHODS: We conducted a nationwide retrospective cohort study of 104 consecutive patients with active UP refractory to conventional therapies, treated at 1 of 15 centers in France or 1 center in Belgium (the GETAID cohort). Patients received at least 1 injection of anti-TNF (infliximab, adalimumab, golimumab) from October 2006 through February 2017. Clinical response was defined as significant improvement in UC-related symptoms, and remission as complete disappearance of UC-related symptoms, each determined by treating physicians. We collected demographic, clinical, and treatment data. The median duration of follow-up was 24 months (interquartile range, 13-51 months). The primary outcome was clinical response of UP to anti-TNF treatment. RESULTS: Overall, 80 patients (77%) had a clinical response to anti-TNF therapy and 52 patients (50%) achieved clinical remission. Extra-intestinal manifestations (odds ratio OR, 0.24; 95% CI, 0.08-0.7), ongoing treatment with topical steroids (OR, 0.14; 95% CI, 0.03-0.73), and ongoing treatment with topical 5-aminosalycilates (OR, 0.21; 95% CI, 0.07-0.62) were significantly associated with the absence of clinical remission. Sixty percent (38/63) of the patients who had endoscopic assessment during follow up had mucosal healing. Among the overall population (n = 104), the cumulative probabilities of sustained clinical remission were 87.6% +/- 3.4% at 1 year and 74.7% +/- 4.8% at 2 years. CONCLUSIONS: In a retrospective study of 104 patients with refractory UP, anti-TNF therapy induced clinical remission in 50% and mucosal healing in 60%. About two thirds of the patients were still receiving anti-TNF therapy at 2 years.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Pineton de Chambrun, Guillaume
Amiot, Aurelien
Bouguen, Guillaume
Viennot, Stephanie
Altwegg, Romain
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Ordas, I., Eckmann, L., Talamini, M., et al. Ulcerative colitis. Lancet 380 (2012), 1606–1619.
Meucci, G., Vecchi, M., Astegiano, M., et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol 95 (2000), 469–473.
Satsangi, J., Silverberg, M.S., Vermeire, S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55 (2006), 749–753.
Gecse, K.B., Lakatos, P.L., Ulcerative proctitis: an update on the pharmacotherapy and management. Expert Opin Pharmacother 15 (2014), 1565–1573.
Pineton de Chambrun, G., Tassy, B., Kollen, L., et al. The treatment of refractory ulcerative colitis. Best Pract Res Clin Gastroenterol 32–33 (2018), 49–57.
Ardizzone, S., Maconi, G., Russo, A., et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55 (2006), 47–53.
Oren, R., Arber, N., Odes, S., et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110 (1996), 1416–1421.
Sandborn, W.J., Tremaine, W.J., Schroeder, K.W., et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 106 (1994), 1429–1435.
Lawrance, I.C., Baird, A., Lightower, D., et al. Efficacy of rectal tacrolimus for induction therapy in patients with resistant ulcerative proctitis. Clin Gastroenterol Hepatol 15 (2017), 1248–1255.
Bageacu, S., Coatmeur, O., Lemaitre, J.P., et al. Appendicectomy as a potential therapy for refractory ulcerative proctitis. Aliment Pharmacol Ther 34 (2011), 257–258.
Molnar, T., Farkas, K., Nagy, F., et al. Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy. Am J Gastroenterol 104 (2009), 1857–1858.
Bouguen, G., Roblin, X., Bourreille, A., et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther 31 (2010), 1178–1185.
Mallet, A.L., Bouguen, G., Conroy, G., et al. Azathioprine for refractory ulcerative proctitis: a retrospective multicenter study. Dig Liver Dis 49 (2017), 280–285.
Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95 quiz e14–15.
Sandborn, W.J., van Assche, G., Reinisch, W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142 (2012), 257–265.
Stidham, R.W., Lee, T.C., Higgins, P.D., et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 39 (2014), 660–671.
Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
Ferrante, M., Vermeire, S., Fidder, H., et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2 (2008), 219–225.
Zampeli, E., Gizis, M., Siakavellas, S.I., et al. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol 5 (2014), 293–303.
Canas-Ventura, A., Marquez, L., Ricart, E., et al. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis 8 (2014), 1287–1293.
